



41

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1621
RECEIVED
JAN 14 2004
TECH CENTER 1600/2900

In re Patent Application of

FANTO et al

Atty. Ref.: 2818-96

Serial No. 09/816,317

Group: 1621

Filed: March 26, 2001

Examiner: Barts

For: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS
FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF
INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES

* * * * *

January 12, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with the duty of disclosure under 37 C.F.R. § 1.55 and in conformance with the procedures of 37 C.F.R. § 1.98, applicants hereby bring the attached literature by Weinstock et al, cited in earlier application Serial No. 09/533,381 filed March 22, 2000 and now pending in Art Unit 1621, to the attention of the examiner. This reference is listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Please return to the undersigned a copy of the attached PTO-1449 with the examiner's initials in the left column [MPEP § 609] with the next communication.

The Commissioner is hereby authorized to charge our Deposit Account No. 14-1140 for any fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Arthur R. Crawford

Reg. No. 25,327

ARC:eaw

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

